Alpha 2.0
Login Register
» Authors » Robert A Marciniak

Robert A Marciniak

Explore the profile of Robert A Marciniak including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 175
Followers 0
Related Specialties
Oncology
Pharmacology
Molecular Biology
Top 10 Co-Authors
Aisha Siddiqa
David Cavazos
Irene Kazhdan
Robin Reed
Richard Montellano
Leonard Guarente
Jeffery Chavez
F Brad Johnson
Shivani B Ruparel
Liuxia Li
Published In
Cancer Gene Ther
Rejuvenation Res
J Oncol
Cancer Res
BMC Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
Modulation of telomeres in alternative lengthening of telomeres type I like human cells by the expression of werner protein and telomerase
Siddiqa A, Cavazos D, Chavez J, Long L, Marciniak R
J Oncol . 2012 May; 2012:806382. PMID: 22545052
The alternative lengthening of telomeres (ALT) is a recombination-based mechanism of telomere maintenance activated in 5-20% of human cancers. In Saccharomyces cerevisiae, survivors that arise after inactivation of telomerase can...
2.
Omega-3 fatty acid inhibition of prostate cancer progression to hormone independence is associated with suppression of mTOR signaling and androgen receptor expression
Friedrichs W, Ruparel S, Marciniak R, deGraffenried L
Nutr Cancer . 2011 Jun; 63(5):771-7. PMID: 21667400
Currently, progression of prostate cancer to androgen independence remains the primary obstacle to improved survival. In order to improve overall survival, novel treatment strategies that are based upon specific molecular...
3.
Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways
Siddiqa A, Long L, Li L, Marciniak R, Kazhdan I
BMC Cancer . 2008 May; 8:129. PMID: 18454859
Background: The oncoprotein HER-2 is over-expressed and/or has undergone gene amplification in between 20 to 30% of breast and ovarian cancers. HER-2 amplified breast cancer is associated with a poor...
4.
Targeting telomerase
Siddiqa A, Cavazos D, Marciniak R
Rejuvenation Res . 2006 Jul; 9(3):378-90. PMID: 16859479
Given the constitutive expression of telomerase in the majority of human tumors, telomerase inhibition is an attractive, broad-spectrum therapeutic target for cancer treatment. Therapeutic strategies for inhibiting telomerase activity have...
5.
Dual luciferase assay system for rapid assessment of gene expression in Saccharomyces cerevisiae
McNabb D, Reed R, Marciniak R
Eukaryot Cell . 2005 Sep; 4(9):1539-49. PMID: 16151247
A new reporter system has been developed for quantifying gene expression in the yeast Saccharomyces cerevisiae. The system relies on two different reporter genes, Renilla and firefly luciferase, to evaluate...
6.
A novel telomere structure in a human alternative lengthening of telomeres cell line
Marciniak R, Cavazos D, Montellano R, Chen Q, Guarente L, Johnson F
Cancer Res . 2005 Apr; 65(7):2730-7. PMID: 15805272
Cancer cells require mechanisms to maintain telomeres. Most use telomerase, but 5% to 20% of tumors use alternative lengthening of telomeres (ALT), a telomerase-independent mechanism that seems to depend on...
7.
Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
Kazhdan I, Marciniak R
Cancer Gene Ther . 2004 Sep; 11(10):691-8. PMID: 15354201
Breast cancer cells are generally resistant to induction of apoptosis by treatment with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). In this study, we demonstrate that both TRAIL-sensitive and TRAIL-resistant breast...